Psychiatric treatment – Page 2

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

The therapeutic potential of microdosing psychedelics in depression

mycolabadmin

This review examines whether taking very small doses of psychedelic drugs like LSD and psilocybin might help treat depression. While users report benefits and some studies show subtle positive effects on mood and thinking, scientists have not yet confirmed whether microdosing actually works as a depression treatment. More research with depressed patients is needed to understand if this approach is truly helpful and safe for regular use.

Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress

mycolabadmin

A study asked 31 palliative care patients about their views on using psilocybin (a compound from magic mushrooms) as a treatment for existential distress—the emotional and spiritual suffering that comes with terminal illness. Over half the patients were interested in trying this therapy, especially if they believed it could help with anxiety and stress. However, patients were concerned about risks like psychosis, the lack of trained therapists, and the potential for doctors to take advantage of them during treatment. The researchers concluded that while psilocybin-assisted therapy shows promise, there needs to be better education and strict safeguards to protect vulnerable patients.

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

mycolabadmin

This study explored how patients with severe depression that didn’t respond to typical treatments experienced psilocybin therapy. Researchers interviewed 11 patients about their experiences and found that building trust with therapists, managing expectations, and having multiple treatment sessions were crucial. Many patients found the experience intense and overwhelming, and most wanted ongoing support to understand what they experienced and how it affected their recovery.

Psychedelics: Safety and Efficacy

mycolabadmin

This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Anhedonia: Current and future treatments

mycolabadmin

Anhedonia is the inability to feel pleasure from activities, which is a significant problem affecting many people with depression and other psychiatric conditions. This review examined many different treatments for anhedonia including medications, brain stimulation techniques, and psychological therapies. The research shows that newer medications like vortioxetine and ketamine work better for anhedonia than older antidepressants, and combining multiple approaches including therapy and lifestyle changes gives the best results.

Acute and Chronic Psilocybin in Mouse Models of Psychiatric Disorders

mycolabadmin

Researchers tested psilocybin (the active compound in magic mushrooms) in mice bred to show obsessive-compulsive behaviors. A single dose of psilocybin reduced compulsive grooming for about a week, but giving it repeatedly over time did not help with anxiety, depression, or compulsive behaviors. The findings suggest psilocybin might work best as a one-time treatment rather than repeated doses, which has implications for how these drugs might be used in future psychiatric treatment.

Psychedelics and the Serotonin Hypothesis of Eating Disorders

mycolabadmin

This review explores how psychedelic drugs like psilocybin (found in certain mushrooms) might help treat eating disorders by promoting flexible thinking and breaking rigid eating patterns. The authors summarize evidence from animal studies and early clinical trials showing that psychedelics work differently than traditional antidepressants by triggering brain changes that help people adopt new, healthier behaviors. While results are promising, more research is needed to determine the best doses, patient populations, and long-term safety.

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

mycolabadmin

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Research Topic: Psychiatric treatment